Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOWR-4: Titrating-dose lonafarnib + ritonavir in chronic hepatitis D virus infection
2015-003077-15Phase 2Completed
- Sponsor
- Eiger BioPharmaceuticals, Inc.
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lonafarnib and ritonavir in hepatitis D (HDV), sponsored by Eiger BioPharmaceuticals, Inc. Primary endpoint: Primary: Safety and tolerability over 24 weeks. Started Sep 2015; status: completed.
02
Drugs
lonafarnibritonavir
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on 2015-003077-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003077-15.